1. 232TiPA multicentre, international neoadjuvant, double-blind, randomized phase III trial comparing fulvestrant to a combination of fulvestrant and palbociclib (CDK 4/6 inhibitor) in patients with operable luminal breast cancer responding to fulvestrant (SAFIA study). (23rd October 2018) Authors: Nabholtz, J-M; Al Saleh, K; Bounedjar, A; Abdel-Razeq, H; Errihani, H; Saadeddin, A; Al Foheidi, M; Ghosn, M; El Zawahry, H; Kandil, A; Abdel-Aziz, N; Dabouz, F; Kullab, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 328PRibociclib (RIBO) + letrozole (LET) in premenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial. (23rd October 2018) Authors: Abdel-Razeq, H; Cottu, P H; Ring, A; De Laurentiis, M; Lu, J; Azim, H A; Zamagni, C; Zhou, K; Wu, J; Menon, L; Martín, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗